Novel agents for managing dyslipidaemia (Q34481800)

2 August 2017

1 reference

title

Novel agents for managing dyslipidaemia (English)

1 reference

2 August 2017

1 reference

Best JD

1

1 reference

PubMed ID

11772294

2 August 2017

Jenkins AJ

series ordinal

2

1 reference

PubMed ID

11772294

2 August 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

1 reference

2 August 2017

10

1 reference

2 August 2017

11

1 reference

2 August 2017

1901-1911

1 reference

Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease.

2 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

ATP-binding cassette transporter A1 (ABCA1) affects total body sterol metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Lifibrol: a novel lipid-lowering drug for the therapy of hypercholesterolemia. Lifibrol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Pros and cons of inhibiting cholesteryl ester transfer protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Novel approaches to treating cardiovascular disease: lessons from Tangier disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Identification of scavenger receptor SR-BI as a high density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Evidence that triglycerides are an independent coronary heart disease risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Dealing with energy demand: the AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Low density lipoprotein oxidation and its pathobiological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Oxidized phospholipids and isoprostanes in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Phenolic antioxidants: a rationale for design and evaluation of novel antioxidant drug for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Protection of low density lipoprotein oxidation by the antioxidant agent IRFI005, a new synthetic hydrophilic vitamin E analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1901

10.1517/13543784.10.11.1901

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11772294